BioCentury | Jan 25, 2019
Clinical News

Tyme shares tumble after pancreatic cancer data

...primary completion date for the trial is in December. SM-88 is a combination of a metyrosine-derivative...
...NASDAQ:TYME), New York, N.Y. Product: SM-88 Business: Cancer Molecular target: NA Description: Combination of a metyrosine-derivative...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Inflammation

...Cytokine release syndrome (CRS) Mouse studies suggest down-regulating catecholamines with NPPA or the TYH inhibitor Demser...
...could include clinical testing of Demser to treat therapy-induced CRS. Bausch Health Companies Inc. markets Demser...
...12, 2018 doi:10.1038/s41586-018-0774-y CONTACT: Verena Staedtke, Johns Hopkins University, Baltimore, Md. email: vstaedt1@jhmi.edu Mary Romeo Demser, metyrosine (ONO-5371) Bausch...
BioCentury | Dec 12, 2018
Preclinical News

Repurposing hypertension drugs to block cytokine release syndrome

...Johns Hopkins University School of Medicine researchers showed that hypertension drug Demser metyrosine and an endogenous...
...inflammation, they showed that infusion of adrenaline increased cytokine production and death, while pretreatment with Demser...
...NYSE:BHC) markets Demser in the U.S. to treat hypertension in patients with pheochromocytoma. Mary Romeo Demser, metyrosine (ONO-5371) PL-3994 Bausch...
BioCentury | Nov 4, 2013
Company News

Valeant Pharmaceuticals, Ono Pharmaceutical deal

...Valeant's Valeant Pharmaceuticals North America LLC affiliate granted Ono exclusive rights to develop and commercialize metyrosine...
Items per page:
1 - 4 of 4